Capricor Therapeutics (CAPR) has been in focus after a Roth Capital analyst lowered expectations, removing a US$80 million milestone and pushing the projected U.S. Deramiocel launch to 2027 following legal action involving NS Pharma.

The legal uncertainty around Deramiocel and the revised commercial timeline appear to be contributing to recent volatility, with the share price down about 18% over the last month but still showing very strong 1 year and multi year total shareholder returns. This suggests sentiment has cooled in the short term, while long term holders remain well ahead.

If this kind of high risk biotech story has your attention, it could be a good moment to see what other healthcare AI related opportunities are emerging through 34 healthcare AI stocks

With Capricor shares down over the past month yet still showing very strong multi year returns and trading at a steep discount to analyst targets, is this an underappreciated growth story, or a stock where the market already sees what is ahead?

Most Popular Narrative: 47.2% Undervalued

Capricor's most followed valuation narrative pegs fair value at $54.67 versus a last close of $28.87, framing a wide gap that rests heavily on Deramiocel and future profitability.

Capricor's strong cash position ($122.8M), combined with the potential to receive a priority review voucher and an $80M milestone payment upon approval, provides a cushion to minimize dilution risk and support commercial launch, which may positively impact future earnings per share and reduce financing overhang.

Curious what has to happen for that valuation to make sense? The narrative focuses on rapid revenue build, steep margin expansion, and a premium future earnings multiple.

Result: Fair Value of $54.67 (UNDERVALUED)

However, the story depends heavily on Deramiocel, and any further FDA setbacks or delays could push out revenue timing and keep cash burn and dilution risk in focus.

Next Steps

With sentiment clearly split between risk and reward, this is the moment to move fast, review the data yourself, and weigh both sides using 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your style better, so put a few minutes aside to scan other focused ideas.

• Target potential bargains that combine quality and price by running your eye over 49 high quality undervalued stocks.
• Prioritise strength and resilience by checking companies in the solid balance sheet and fundamentals stocks screener (46 results).
• Spot opportunities others might overlook by scanning the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.